Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence

International Journal of Endocrinology
Jia LiuGuang Wang

Abstract

Graves' disease (GD) is the most common cause of hyperthyroidism worldwide. Current therapeutic options for GD include antithyroid drugs (ATD), radioactive iodine, and thyroidectomy. ATD treatment is generally well accepted by patients and clinicians due to some advantages including normalizing thyroid function in a short time, hardly causing hypothyroidism, and ameliorating immune disorder while avoiding radiation exposure and invasive procedures. However, the relatively high recurrence rate is a major concern for ATD treatment, which is associated with multiple influencing factors like clinical characteristics, treatment strategies, and genetic and environmental factors. Of these influencing factors, some are modifiable but some are nonmodifiable. The recurrence risk can be reduced by adjusting the modifiable factors as much as possible. The titration regimen for 12-18 months is the optimal strategy of ATD. Levothyroxine administration after successful ATD treatment was not recommended. The addition of immunosuppressive drugs might be helpful to decrease the recurrence rate of GD patients after ATD withdrawal, whereas further studies are needed to address the safety and efficacy. This paper reviewed the current knowledge of A...Continue Reading

References

Dec 1, 1977·Archives of Disease in Childhood·T SatoH Nakajima
Oct 30, 1992·Clinica Chimica Acta; International Journal of Clinical Chemistry·J ReglinskiJ A Thomson
Mar 1, 1990·The Journal of Clinical Endocrinology and Metabolism·H AllannicV Derennes
Oct 1, 1987·Annals of Internal Medicine·B L SolomonL Wartofsky
Aug 1, 1985·The Journal of Clinical Endocrinology and Metabolism·F Azizi
Jan 1, 1995·Annals of the Rheumatic Diseases·J A Da Silva
May 1, 1994·Journal of the American Geriatrics Society·T YamadaK Hashizume
Feb 11, 1999·Journal of Endocrinological Investigation·L ChiovatoA Pinchera
Mar 17, 2000·The Journal of Clinical Endocrinology and Metabolism·A AllahabadiaJ A Franklyn
Nov 9, 2000·The New England Journal of Medicine·A P Weetman
Feb 21, 2003·Thyroid : Official Journal of the American Thyroid Association·Rudolf HoermannUNKNOWN Basedow Study Group
Mar 5, 2005·The New England Journal of Medicine·David S Cooper
Jul 11, 2006·Endocrine Journal·Kyuzi KamoiMasashi Miyakoshi
Oct 14, 2006·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·B QuadbeckUNKNOWN Basedow Study Group
Feb 8, 2007·The Journal of Clinical Endocrinology and Metabolism·Daniel El FassiLaszlo Hegedüs
Mar 29, 2007·The Journal of Clinical Endocrinology and Metabolism·Hirotoshi NakamuraNoboru Hamada
May 17, 2007·Medicinal Chemistry·Tina WertenbruchMatthias Schott
Oct 24, 2007·Thyroid : Official Journal of the American Thyroid Association·Kyung Won KimBo Youn Cho
Jun 11, 2009·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·D GlowackaA K Eckstein
Apr 30, 2010·Current Opinion in Pharmacology·Femke BaekeChantal Mathieu
Dec 31, 2010·Thyroid : Official Journal of the American Thyroid Association·Laura ElbersWilmar Wiersinga
Mar 2, 2011·European Journal of Endocrinology·Allan CarléPeter Laurberg
Aug 13, 2011·Thyroid : Official Journal of the American Thyroid Association·Peter LaurbergInge Bülow Pedersen
Jan 10, 2012·Psychoneuroendocrinology·Grigoris EffraimidisWilmar M Wiersinga
Mar 1, 2008·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Francisco Morales GarcíaFernando Villamil Fernández
Mar 2, 2013·Clinical Endocrinology·Inge Bülow PedersenPeter Laurberg

❮ Previous
Next ❯

Citations

Aug 2, 2018·Expert Opinion on Drug Safety·Lin-Chau ChangTien-Chun Chang
Mar 13, 2019·The Journal of Clinical Endocrinology and Metabolism·Jonathon O RussellRalph P Tufano
Mar 12, 2020·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Maorong Wang, Yerong Yu
Mar 5, 2021·Thyroid Research·Yotsapon ThewjitcharoenThep Himathongkam
Aug 20, 2021·Frontiers in Cell and Developmental Biology·Fei ShenBo Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.